Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain

Conclusions: Overall, our findings provide proof of concept for a new class of analgesics that target T-type channel deubiquitination.

http://www.molecularpain.com/content/11/1/12

Source: Molecular Pain - March 14, 2015 Category: Molecular Biology Authors: Vinicius GadottiAgustin CaballeroN BergerClare GladdingLina ChenTom PfeiferGerald Zamponi Source Type: research